)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
SCYNEXIS (SCYX) investor relations material
SCYNEXIS Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary13 Aug, 2025
Executive summary
Focused on novel antifungal agents, with ibrexafungerp approved for VVC/RVVC and SCY-247 in Phase 1 trials; first new patient dosed in Phase 3 MARIO study after FDA hold lifted, triggering a $10M milestone from GSK, which is disputed.
Transfer of BREXAFEMME NDA to GSK expected by end of 2025 for regulatory relaunch in 2026.
Securities class action lawsuit dismissed with leave to amend; ongoing derivative lawsuits related to manufacturing disclosures.
Received Nasdaq notice for non-compliance with minimum bid price; 180 days to regain compliance.
Financial highlights
Q2 2025 revenue was $1.4M, up 85% year-over-year, mainly from GSK license; six-month revenue was $1.6M, down 23%.
Net loss for Q2 2025 was $6.9M ($0.14 per share), improved from $14.5M ($0.30 per share) in Q2 2024.
Operating expenses for Q2 2025 were $10.9M, up 9.5% year-over-year; R&D expenses rose 5% to $7.1M, SG&A up 20% to $3.8M.
Cash, cash equivalents, and investments totaled $46.5M as of June 30, 2025, down from $75.1M at year-end 2024.
Repayment of $14.0M convertible debt in March 2025.
Outlook and guidance
Cash runway projected into Q4 2026 based on current operating plan.
Anticipates continued significant R&D and SG&A expenses; may require additional capital through equity, debt, or partnerships.
Future capital needs depend on milestone achievements, clinical progress, regulatory outcomes, and collaborations.
Phase 1 SAD/MAD data for SCY-247 expected in Q3 2025.
BREXAFEMME NDA transfer to GSK targeted by end of 2025, with regulatory relaunch discussions planned for 2026.
GSK's view on the MARIO study milestones?
When will the BREXAFEMME NDA transfer complete?
Note factors impacting warrant liability changes.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next SCYNEXIS earnings date
Q3 202524 Oct, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
Frequently asked questions
SCYNEXIS Inc. is a biotechnology company focused on the research, development, and commercialization of innovative therapies for fungal infections. The company's lead product, based on a novel antifungal platform, is designed to address severe and drug-resistant fungal infections in both hospital and outpatient settings. SCYNEXIS develops treatments for conditions with significant unmet medical needs, with a particular emphasis on antifungal agents targeting life-threatening infections. The company is headquartered in Jersey City, USA, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage